Overall, 0.37% of GLP-1 users in the matched comparison were diagnosed with smell or taste problems, compared to 0.22% of non-users
Although the triple agonist retatrutide has been demonstrated to be a powerful agent in the setting of diabetes (78) and/or obesity (77), the kidney effects are poorly characterized
doi: 10.1002/dmrr.3070 Summary Keywords GLP-1 receptor agonists, thyroid disorders, thyroid cancer, meta-analysis, randomized controlled trials Citation Hu W, Song R, Cheng R, Liu C, Guo R, Tang W, Zhang J, Zhao Q, Li X and Liu J (2022) Use of GLP-1 Receptor Agonists and Occurrence of Thyroid Disorders: a Meta-Analysis of Randomized Controlled Trials
However, more than half of this cohort, 56%, said that if cost and availability were not an issue, they would begin using GLP-1 medications for weight loss